title: Bleomycin enhances random integration of transfected DNA into a human genome.
abstract: In mammalian cells, nonhomologous (illegitimate) recombination is a predominant pathway to repair DNA double-strand breaks. We have shown that DNA topoisomerase II inhibitors are capable of enhancing random integration of foreign DNA via nonhomologous recombination. Since this enhancement is likely due to stabilized DNA strand breaks, we examined the effect of a radiomimetic antitumor drug, bleomycin (BLM), on nonhomologous recombination. We found that BLM greatly enhances the random integration of transfected plasmids into human cells. Importantly, this enhancement was independent of the molecular form of the plasmid, the cell type or the transfection method, suggesting that the BLM effect is intrinsically general. Transient expression analysis revealed no stimulation of reporter gene expression by the drug, suggesting that the effect is not attributable to increased uptake and/or accumulation of transfected DNA in the drug-treated cell nuclei. In addition, the comet assay and flow cytometric analyses revealed the occurrence of low but significant strand breaks in cells treated with the BLM concentration which maximally enhanced the integration. These results strongly suggest that BLM acts directly at a nonhomologous recombination reaction that is initiated through DNA strand breaks, promoting the integration process of transfected plasmids into human chromosomes. Our findings will facilitate the understanding of DNA integration events through nonhomologous recombination and the development of transfection protocols with higher efficiencies.
authors.affiliation: Kihara Institute for Biological Research, Yokohama City University, Yokohama, Japan.
authors.forename: C
authors.initials: C
authors.lastname: Nakayama
authors.forename: N
authors.initials: N
authors.lastname: Adachi
authors.forename: H
authors.initials: H
authors.lastname: Koyama
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology*; D002460:Cell Line; D004247:DNA / Q000187:drug effects* / Q000235:genetics* / Q000378:metabolism; D004249:DNA Damage; D004260:DNA Repair; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D017930:Genes, Reporter / Q000187:drug effects; D015894:Genome, Human; D006367:HeLa Cells; D006801:Humans; D008156:Luciferases / Q000235:genetics; D010957:Plasmids / Q000235:genetics; D011995:Recombination, Genetic / Q000187:drug effects*; D059005:Topoisomerase II Inhibitors; D014162:Transfection
chemical_list: D000903:Antibiotics, Antineoplastic; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D001761:Bleomycin; D004247:DNA; D008156:Luciferases